Related Experiment Video
Updated: May 24, 2026
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
Development of biochemical assays for the identification of eIF4E-specific inhibitors
Carlo Visco1, Claudia Perrera, Sandrine Thieffine
1Biotechnology Department, Nerviano Medical Sciences, Nerviano (MI), Italy.
Abstract:
Control of mRNA translation plays a critical role in cell growth, proliferation, and differentiation and is tightly regulated by AKT and RAS oncogenic pathways. A key player in the regulation of this process is the mRNA 5' cap-binding protein, eukaryotic translation initiation factor 4E (eIF4E). eIF4E contributes to malignancy by selectively enabling the translation of a limited pool of mRNAs that generally encode key proteins involved in cell cycle progression, angiogenesis, and metastasis. Several data indicate that the inhibition of eIF4E in tumor cell lines and xenograft models impairs tumor growth and induces apoptosis; eIF4E, therefore, can be considered a valuable target for cancer therapy. Targeting the cap-binding pocket of eIF4E should represent a way to inhibit all the eIF4E cellular functions. We present here the development and validation of different biochemical assays based on fluorescence polarization and surface plasmon resonance techniques. These assays could support high-throughput screening, further refinement, and characterization of eIF4E inhibitors, as well as selectivity assessment against CBP80/CBP20, the other major cap-binding complex of eukaryotic cells, overall providing a robust roadmap for development of eIF4E-specific inhibitors.
Insights
Eukaryotic translation initiation factor 4E (eIF4E) drives cancer by promoting translation of key malignant proteins. New biochemical assays enable development of targeted eIF4E inhibitors for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- mRNA translation control is vital for cell growth and is dysregulated in cancer by oncogenic pathways.
- Eukaryotic translation initiation factor 4E (eIF4E) selectively translates mRNAs encoding proteins crucial for tumor progression, including angiogenesis and metastasis.
- eIF4E is a validated therapeutic target in cancer, as its inhibition halts tumor growth and induces apoptosis.
Purpose of the Study:
- To develop and validate biochemical assays for high-throughput screening and characterization of eIF4E inhibitors.
- To provide a robust roadmap for the development of eIF4E-specific inhibitors targeting the cap-binding pocket.
- To assess the selectivity of potential inhibitors against other cap-binding complexes like CBP80/CBP20.
Main Methods:
- Development of biochemical assays utilizing fluorescence polarization (FP).
- Implementation of surface plasmon resonance (SPR) techniques for assay validation.
- Establishment of selectivity assays against CBP80/CBP20.
Main Results:
- Validated FP and SPR assays suitable for high-throughput screening of eIF4E inhibitors.
- Demonstrated the capability of these assays to refine and characterize eIF4E inhibitors.
- Established methods for assessing inhibitor selectivity against other cap-binding complexes.
Conclusions:
- Biochemical assays based on FP and SPR provide a powerful platform for developing eIF4E-specific cancer therapeutics.
- Targeting the eIF4E cap-binding pocket is a promising strategy for cancer treatment.
- These validated assays facilitate the discovery and optimization of novel eIF4E inhibitors.
